KR20200089242A - Composition containing complex extracts for preventing, improving or treating dyslipidemia - Google Patents

Abstract

The present invention provides a composition containing a complex extract composed of an Angelica gigas extract, a Cynanchum wilfordii extract, and a Ginkgo biloba leaf extract, as an active component. The composition of the present invention has an excellent blood clot formation inhibitory effect by a synergistic effect of the complex extract composed of the Angelica gigas extract, the Cynanchum wilfordii extract, and the Ginkgo biloba leaf extract, and at the same time has excellent blood cholesterol lowering effect and blood triglyceride lowering effect. Therefore, the composition of the present invention can be implemented as medicine or health functional food for improving blood circulation, and for preventing, alleviating or treating thrombosis and dyslipidemia.

Description

Composition containing complex extracts for preventing, improving or treating dyslipidemia}

The present invention relates to a composition for improving blood circulation, including a complex extract, and more specifically, to a variety of medicinal uses or health functional food urethra of the herbal extract complex based on the effect of inhibiting thrombus formation of the herbal extract, blood cholesterol lowering effect, etc. will be.

Recently, not only in developed countries, but also in Korea, with the increase in obesity due to over-nutrition due to the westernization of eating habits, circulatory diseases such as arteriosclerosis, brain hemorrhage, hypertension, heart disease, stroke, and cerebral infarction have ranked first and second in death. As these adult diseases develop into the modern society, they frequently occur in middle-aged and older adults due to changes in dietary habits and internal and external environmental stress. In addition, the diseases may be caused by blood vessels blocked by various causes, for example, when the cardiovascular vessels are blocked, myocardial infarction may occur, and when the blood vessels in the brain are blocked, cerebral infarction may occur. In addition, if the stroke continues, stroke symptoms may appear and result in loss of life. Stroke is the third highest cause of death in adults in the United States, and it is known to be the biggest contributor to disability. The main cause of these diseases is known as thrombus, which is recognized as a pathology mediated by excessive platelet aggregation. In addition, when a blood clot is formed, blood vessels in the portion are narrowed or blocked, and thus blood circulation is disturbed. In addition, an increase in the concentration of cholesterol or triglycerides in the blood may cause disorders in blood circulation.

Accordingly, many researches have been conducted on pharmaceutical materials or health functional food materials that can inhibit blood clot formation and effectively control blood cholesterol and triglyceride concentrations to improve blood circulation and prevent or treat thrombotic diseases. On the other hand, natural food and medicine materials have great significance in the economic and industrial sector, and since most of them have no side effects on the human body, the development of natural food and medicine materials that are effective in improving blood circulation is urgently required.

In connection with a natural food and drug material having an effect of improving blood circulation, Korean Patent Publication No. 10-1404168 discloses a pharmaceutical composition for preventing or treating thrombosis containing an butanol fraction of Angelica gigas ethanol extract as an active ingredient It is. In addition, Korean Patent Publication No. 10-2011-0125960 discloses a pharmaceutical composition for reducing thrombosis, which contains an extract of ethanol of Baekshou ( Cynanchum wilfordii ) as an active ingredient. In addition, products containing ginkgo biloba extract that help improve blood circulation are commercially available. In addition, Korean Patent Publication No. 10-2018-0042035 discloses a pharmaceutical composition for preventing or treating dyslipidemia containing Angelica gigas extract as an active ingredient. Further, in Republic of Korea-A-10-2011-0125958 call back sewage (Cynanchum wilfordii ) A pharmaceutical composition for lowering cholesterol in blood containing an ethanol extract as an active ingredient is disclosed . In addition, U.S. Patent Publication No. 2008/0254155 discloses a composition for lowering cholesterol in the blood that includes an extract of ginkgo biloba as an active ingredient.

The present invention is derived under the conventional technical background, the purpose of the present invention is a variety of pharmaceutical uses or health functions, such as blood circulation improvement, thrombotic disease prevention, improvement or treatment of a complex extract consisting of Angelica keiskei koidus extract, white sorghum extract and ginkgo biloba extract In providing food use.

The inventors of the present invention conducted a study to develop an extract having the efficacy of inhibiting thrombus formation against a large number of natural products that are secured in safety compared to synthetic chemicals. As a result, it was confirmed that the complex extract consisting of Angelica keiskei koidus extract, Baeksuo extract and Ginkgo biloba leaf extract has excellent thrombus formation inhibitory effect by synergy and at the same time has excellent blood cholesterol lowering effect and blood triglyceride lowering effect. Was completed.

In order to achieve the above object, an example of the present invention provides a composition for improving blood circulation, which includes a complex extract composed of a true Angelica extract, a white sorghum extract, and a ginkgo biloba extract as an active ingredient.

In order to achieve the above object, an example of the present invention provides a composition for preventing, improving or treating a thrombotic disease, comprising a complex extract composed of an Angelica keiskei kombu extract, a white sorghum extract and a ginkgo leaf extract as an active ingredient.

In order to achieve the above object, an example of the present invention provides a composition for preventing, improving or treating dyslipidemia comprising a complex extract consisting of Angelica keiskei kombu extract, Baeksuo extract and Ginkgo biloba extract as an active ingredient.

The composition preferably takes the form of a pharmaceutical composition or a food composition.

The composition of the present invention has excellent thrombus formation inhibitory effect by synergistic action of a complex extract composed of a true Angelica extract, white sorghum extract, and ginkgo biloba extract, and at the same time, has excellent blood cholesterol lowering effect and blood triglyceride lowering effect. Therefore, the composition of the present invention can be embodied as a drug for the purpose of preventing, improving or treating blood circulation improvement, thrombotic disease, dyslipidemia, and health functional food.

1 is a result of analyzing the antioxidant efficacy of the complex extract prepared in Preparation Example 4 of the present invention using a DPPH test method.
Figure 2 shows the results of the anti-thrombotic efficacy evaluation of the complex extract using a thrombosis-induced animal model as a protection (%) value.
FIG. 4 shows the triglyceride content in plasma among the experimental results using the obese-inducing animal model, FIG. 5 shows the total cholesterol content in plasma among the experimental results using the obese-inducing animal model, and FIG. 6 shows the obese-inducing animal Among the experimental results using the model, it shows the LDL cholesterol content in plasma.

Hereinafter, terms used in the present invention will be described.

As used herein, the terms "pharmaceutically acceptable" and "foodly acceptable" mean not significantly stimulating the organism and not inhibiting the biological activity and properties of the active substance administered.

As used herein, the term "prevention" refers to all actions that inhibit or delay the progression of symptoms of a specific disease (eg, thrombotic disease) by administration of a composition of the invention.

As used herein, the term "improvement" means any action that at least reduces the severity of parameters associated with the condition being treated, such as symptoms.

As used herein, the term "treatment" means any action that improves or beneficially alters the symptoms of a particular disease (eg, thrombotic disease) by administration of the composition of the invention.

As used herein, the term "administration" means providing a subject composition of the present invention to an individual in any suitable way. At this time, the individual refers to all animals, such as humans, monkeys, dogs, goats, pigs, or rats, with diseases that may improve symptoms of a specific disease by administering the composition of the present invention.

The term "pharmaceutically effective amount" used in the present invention means an amount sufficient to treat a disease at a reasonable benefit or risk ratio applicable to medical treatment, which is the type, severity, drug activity, drug of the individual. Sensitivity to, time of administration, route of administration and rate of discharge, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical field can be determined.

Hereinafter, the present invention will be described in detail. The present invention includes a composition comprising a complex extract consisting of extracts of three herbal medicines as an active ingredient. The complex extract is specifically composed of Angelica keiskei kombu extract, Baeksuo extract and ginkgo biloba extract. The composition of the present invention improves blood circulation; Preventing, improving or treating thrombotic diseases; It can be used for various medicines or health functional foods such as dyslipidemia prevention, improvement or treatment.

The Angelica gigas is a perennial plant that belongs to the mountain type family of the mountain type tree, Ipanhwa-gun, and uses its roots as a medicinal material. The white snail ( Cynanchum wilfordii ) is a vine perennial plant belonging to the genus Cynanchum of the Asclepiadaceae family, and uses its roots as a medicinal material. In the present invention, the site of the plant for obtaining the Angelica keiskei koi extract or Baeksuo extract is not greatly limited such as roots, stems, leaves, flowers, seeds, and is preferably a root when considering efficacy.

The complex extract, which is the active ingredient of the composition according to the present invention, can be prepared by various methods. For example, the composite extract may be prepared by mixing the Angelica keiskei, white snails and ginkgo biloba and adding an extracting solvent thereto and extracting the mixed extract, again adding and fractionating alcohol having 3 to 8 carbons to the mixed extract. It can also be manufactured. In addition, the composite extract may be prepared by obtaining a true Angelica extract, a white sorghum extract, and a ginkgo biloba extract, respectively, from a true Angelica, white sorghum, and ginkgo leaf. Specifically, the Angelica extract, Baeksuo extract, or Ginkgo biloba extract constituting the complex extract may be prepared using a conventional extraction method known in the art, for example, a solvent extraction method. The extraction solvent used in the solvent extraction method is water, lower alcohol having 1 to 4 carbon atoms (for example, methanol, ethanol, propanol and butanol) or a mixture thereof, hydrous lower alcohol, propylene glycol, 1,3-butylene glycol. , Glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane, and mixtures thereof, and may be selected from water, alcohols, or mixtures thereof. It is more preferable that it is hydrous alcohol. When water is used as the extraction solvent, water is preferably hot water. In addition, when alcohol is used as the extraction solvent, the alcohol is preferably a lower alcohol having 1 to 4 carbon atoms, and the lower alcohol is more preferably selected from methanol or ethanol. In addition, when using hydrous alcohol as the extraction solvent, the alcohol content is preferably 50 to 90%, and more preferably 60 to 85%. On the other hand, it is apparent to those skilled in the art that, in addition to the above-described extraction solvent, a true Angelica extract, white sorghum extract, or ginkgo biloba extract, which exhibits substantially the same effect, can be obtained using other extraction solvents. In addition, the extract of the Angelica Angelica constituting the complex extract, the extract of Baeksuo or Ginkgo biloba, as well as the extract by the above-mentioned extraction solvent, include extracts, fractions, purified products obtained through other conventional extraction methods, and extracts that have undergone a fermentation process. Can. For example, extraction by supercritical fluid extraction using carbon dioxide, extraction by ultrasonic extraction, separation using an ultrafiltration membrane having a constant molecular weight cut-off value, or various chromatography (size, charge, The active fraction obtained through various purification and extraction methods additionally performed, such as separation by hydrophobicity or affinity), separation by fermentation products of various microorganisms, is also included in the extract of the present invention. In general, supercritical fluids have the properties of liquids and gases that the gas has when it reaches a critical point under high temperature and high pressure conditions, and have a chemically polarity similar to a non-polar solvent. Due to these characteristics, supercritical fluids are used for extraction of fat-soluble materials. Used (J. Chromatogr. A. 1998; 479:200-205). Carbon dioxide becomes a supercritical fluid having both liquid and gaseous properties through the process of pressure and temperature reaching a critical point through the operation of a supercritical fluid device, and as a result, solubility in fat-soluble solute increases. When the supercritical carbon dioxide passes through an extraction container containing a certain amount of sample, the fat-soluble substance contained in the sample is extracted from the supercritical carbon dioxide. After extracting the fat-soluble substance, passing the supercritical carbon dioxide containing a small amount of the co-solvent back to the sample remaining in the extraction container may allow components not extracted with pure supercritical carbon dioxide to be extracted. The supercritical fluid used in the supercritical extraction method of the present invention can effectively extract an active ingredient by using supercritical carbon dioxide or a mixed fluid in which a co-solvent is additionally mixed with carbon dioxide. As such a co-solvent, one or two or more mixtures selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether can be used. Most of the extracted sample contains carbon dioxide, which is volatilized into the air at room temperature, and the co-solvent can be removed by a vacuum evaporator. In addition, the ultrasonic extraction method is an extraction method that uses energy generated by ultrasonic vibration, and ultrasonic waves can destroy insoluble solvents contained in a sample in a water-soluble solvent, and are located around due to the high local temperature generated at this time. Since the kinetic energy of the reactant particles is increased, sufficient energy necessary for the reaction is obtained, and high pressure is induced by the impact effect of ultrasonic energy to increase the mixing effect of the substance and the solvent contained in the sample, thereby increasing extraction efficiency. As the extraction solvent that can be used for the ultrasonic extraction method, one or a mixture of two or more selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether can be used. The extracted sample can be vacuum filtered to recover the filtrate, then removed with a vacuum evaporator, and an extract can be obtained through a conventional extract preparation method of freeze drying. In addition, the extract of the Angelica constituting the complex extract, the extract of Baeksuo or Ginkgo biloba also includes the extract that has undergone the fermentation process. For example, the fermented extract of the Angelica can be prepared as follows. Finely shredded Angelica Angelica to a size of about 100 to 500 mesh, and then added a conventional culture medium for microorganisms so that the jimo concentration is 1 to 50 g/L, and microorganisms such as yeast strains or lactic acid bacteria are added in an amount of 10,000 to 100,000 cfu/L. Add. Subsequently, the cells are cultured for about 5 to 10 days in aerobic or anaerobic conditions under normal microbial culture conditions such as a culture temperature of 30 to 37°C and a pH of 5 to 7. Then, fermentation extract of Angelica Angelica can be obtained through aging and filtration. The fermented extract of Baeksuo or the fermented extract of ginkgo biloba can also be prepared through the same process.

In the composition according to the present invention, the mixing ratio of the Angelica kerosene extract, Baeksu-o extract and Ginkgo biloba extract constituting the complex extract as an active ingredient is not significantly limited. For example, the weight ratio of Angelica keiskei koidus extract, Baeksuo extract and Ginkgo biloba extract in the complex extract may be selected from 1: (0.5~2): (0.5~2), and considering synergistic action, 1:(0.6 ~1.5): It is preferably selected from (0.6-1.5), and more preferably selected from 1: (0.8-1.2): (0.8-1.2).

The complex extract used as an active ingredient in the composition of the present invention has excellent thrombus formation inhibitory effect by synergistic action of the combination of Angelica keiskei kombu extract, Baeksuo extract and Ginkgo biloba extract, and at the same time has excellent blood cholesterol lowering effect and blood triglyceride lowering effect Have Therefore, the composition of the present invention can be implemented as a medicine for the purpose of preventing, improving or treating blood circulation improvement, thrombotic disease, dyslipidemia, and health functional food. In addition, the complex extract used as an active ingredient in the composition of the present invention has excellent radical scavenging activity and can also be used as a component of an antioxidant composition. In addition, the complex extract used as an active ingredient in the composition of the present invention may be used as a component of a composition for preventing, improving or treating obesity. In addition, the complex extract used as an active ingredient in the composition of the present invention may be used as a component of a composition for preventing, improving or treating metabolic syndrome. The metabolic syndrome is a disease in which at least one disease selected from hyperlipidemia, cardiovascular disease, hypertension or arteriosclerosis occurs simultaneously with obesity.

In the present invention, thrombotic disease is a disease caused by thrombi, and its type is not greatly limited, for example, arterial thrombosis, venous thrombosis, pulmonary embolism, chronic venous ischemia, lower extremity varicose veins, deep venous thrombosis, arteriosclerosis, cerebral hemorrhage, stroke And it may be any one or more selected from the group consisting of cerebral infarction.

In the present invention, dyslipidemia refers to a condition in which total cholesterol, LDL cholesterol, and triglycerides are increased or HDL cholesterol is decreased in the blood, and any one or more selected from the group consisting of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia. Can. The hyperlipidemia refers to a state in which lipids including cholesterol and triglycerides are increased in the blood. Hyperlipidemia may increase the risk of coronary artery disease, such as arteriosclerosis or myocardial infarction, although it does not exhibit symptoms. The hypercholesterolemia is a condition in which cholesterol is increased in the blood, and total cholesterol and LDL cholesterol are high. The hypertriglyceridemia refers to a state in which triglycerides are increased in the blood.

The composition comprising the complex extract of the present invention as an active ingredient may be embodied as a pharmaceutical composition, a food additive, a food composition (especially a health functional food), or a feed additive depending on the purpose or aspect of use, and a complex extract in the composition The content of can also be adjusted in various ranges depending on the specific form of the composition, purpose of use, and aspect.

The content of the complex extract as an active ingredient in the pharmaceutical composition of the present invention is not significantly limited, for example, 0.1 to 99% by weight, preferably 0.5 to 50% by weight, more preferably 1 to 30 based on the total weight of the composition. Weight percent. In addition, the pharmaceutical composition of the present invention may further include additives such as a pharmaceutically acceptable carrier, excipient or diluent in addition to the complex extract. Carriers, excipients and diluents that may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In addition, the pharmaceutical composition of the present invention improves blood circulation in addition to the complex extract; Preventing, improving or treating thrombotic diseases; It may further contain one or more known active ingredients having the effect of preventing, improving or treating dyslipidemia. The pharmaceutical composition of the present invention may be formulated into a formulation for oral administration or a formulation for parenteral administration by a conventional method, and when formulated, a filler, a bulking agent, a binder, a wetting agent, a disintegrant, a surfactant, etc. It can be prepared using diluents or excipients. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.These solid preparations include at least one excipient such as starch, calcium carbonate, water, etc. It can be prepared by mixing Sucrose, Lactose, or gelatin. In addition, lubricants such as magnesium stearate talc may be used in addition to simple excipients. Liquid preparations for oral administration include suspending agents, intravenous solutions, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, can be included. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin may be used. Furthermore, it can be preferably formulated in accordance with each disease or ingredient using methods disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA, or by appropriate methods in the art. The pharmaceutical composition of the present invention may be administered orally or parenterally to mammals, including humans, according to the desired method, and the parenteral administration methods include external application to the skin, intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, and muscle. Intra-injection or intra-thoracic injection. The dosage of the pharmaceutical composition of the present invention is not particularly limited as long as it is a pharmaceutically effective amount, and the range thereof depends on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate and disease severity. Varies. The typical daily dosage of the pharmaceutical composition of the present invention is not greatly limited, and can be selected from 1 to 1000 mg/kg, for example, based on the complex extract as an active ingredient, and from 10 to 500 mg/kg It is preferably selected, and more preferably 50 to 250 mg/kg. The number of times of administration of the pharmaceutical composition of the present invention is also not greatly limited, and can be administered, for example, once or several times a day.

The content of the complex extract as an active ingredient in the food composition of the present invention is not significantly limited, and is 0.01 to 50% by weight, preferably 0.1 to 25% by weight, more preferably 0.5 to 10% by weight based on the total weight of the composition Can. Food composition of the present invention includes a form of pills, powders, granules, needles, tablets, capsules, or liquids, and examples of specific foods include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, Other dairy products including noodles, gums, and ice creams, various soups, beverages, teas, functional waters, drinks, alcoholic beverages, and vitamin complexes are all included. The food composition of the present invention may contain various flavoring agents or natural carbohydrates as an additional component in addition to the complex extract as an active ingredient. In addition, the food composition of the present invention, various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol , Carbonic acid used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain flesh for the preparation of natural fruit juice, fruit juice beverages and vegetable beverages. These ingredients can be used independently or in combination. The above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the flavoring agent, natural flavoring agents such as taumatin and stevia extract or synthetic flavoring agents such as saccharin and aspartame may be used.

Hereinafter, the present invention will be described in more detail through examples. However, the following examples are only for clearly illustrating the technical features of the present invention, and are not intended to limit the protection scope of the present invention.

1. Angelica extract, Baek Su-oh Preparation of extract, ginkgo biloba extract and complex extract

Preparation Example 1: Preparation of Angelica Angelica extract

The ground part of dried Angelica gigas purchased from the Gyeongdong Herb Market was ground and powdered. Thereafter, about 5 times 70% alcohol was added to the Angelica keiskei koid powder sample, extracted twice at 80° C. for about 4 hr, and then filtered. Thereafter, the filtered extract was concentrated under reduced pressure and freeze-dried to obtain an Angelica keiskei koidz extract. The yield of Angelica keiskei koidz was about 32%.

Preparation Example 2: Preparation of Baeksuo extract

The dried white sorghum ( Cynanchum wilfordii ) purchased from the Gyeongdong Herb Market was ground and powdered. Then, about 5 times as much as 70% alcohol was added to the baeksuo powder sample and extracted twice at 80° C. for about 4 hr, followed by filtration. Then, the filtered extract was concentrated under reduced pressure and freeze-dried to obtain a white shou extract. The yield of Baeksuo extract was about 29.2%.

Preparation Example 3: Preparation of ginkgo biloba extract

Dried Ginkgo biloba leaves purchased at the Gyeongdong Herb Market were ground and powdered. Thereafter, about 5 times 70% alcohol was added to the ginkgo biloba powder sample, extracted twice at 80° C. for about 4 hr, and then filtered. Thereafter, the filtered extract was concentrated under reduced pressure and lyophilized to obtain ginkgo biloba extract. The yield of ginkgo biloba extract was about 27.3%.

Preparation Example 4: Preparation of complex extract

A mixture extract was prepared by mixing the Angelica keiskei koidz extract prepared in Preparation Example 1, Baekshou extract prepared in Preparation Example 2, and ginkgo biloba extract extracted from Preparation Example 3 in a weight ratio of 1:1:1.

2. Analysis of antioxidant efficacy of complex extracts

The antioxidant efficacy of the complex extract prepared in Preparation Example 4 was measured using the DPPH test method. First, DPPH (1,1-diphenyl-2-2hydrazyl) reagent was prepared by dissolving DPPH (1,1-diphenyl-2-2hydrazyl) in methanol to a concentration of 0.1 mM in the light-ruptured state.

Thereafter, the complex extracts prepared in Preparation Example 4 were added to DPPH (1,1-diphenyl-2-2hydrazyl) reagent at concentrations of 50 µg/ml, 100 µg/ml, 500 µg/ml, and 1000 µg/ml, respectively. After reacting for 20 minutes under the condition of blocking the light, absorbance was measured at a wavelength of 517 nm using a microplate reader. Meanwhile, as a positive control, ascorbic acid was added to a DPPH (1,1-diphenyl-2-2hydrazyl) reagent at a concentration of 100 µg/ml. Thereafter, DPPH radical scavenging activity (%) was calculated using Equation 1 below.

[Equation 1]

1 is a result of analyzing the antioxidant efficacy of the complex extract prepared in Preparation Example 4 of the present invention using a DPPH test method. In FIG. 1,'Control(+)' of the X-axis represents a positive control, and'ACG-1 extract' represents a composite extract prepared in Preparation Example 4. In addition, the results of the antioxidant efficacy analysis of the composite extract prepared in Preparation Example 4 are shown in Table 1 below.

Processed sample Treatment concentration (µg/ml) DPPH radical scavenging activity(%) IC ₅₀ of complex extracts
(Μg/ml) Composite extract prepared in Preparation Example 4 50 5.6 360.5 100 25.0 500 49.2 1000 86.8

3. Platelet aggregation of complex extracts Restraint Measure

The ability of the complex extract prepared in Preparation Example 4 to inhibit platelet aggregation derived from the human body was measured by a turbidity measurement method using an Aggregometer (Chrono-Log Co., Ltd., Havertown, PA, USA). First, the Angelica Angelica extract prepared in Preparation Example 1, Baeksuo Extract prepared in Preparation Example 2, Ginkgo Leaf Extract prepared in Preparation Example 3, and the complex extract prepared in Preparation Example 4 are each dissolved in various concentrations in 1% DMSO solution. To prepare a sample solution. Thereafter, the human-derived platelets were incubated for 3 minutes at 37° C., and then the sample solution was processed and aggregation was induced with collagen, a platelet aggregation-inducing substance, and the platelet aggregation rate was measured for 6 minutes. Table 2 below shows the results of measuring platelet aggregation inhibitory ability of Angelica keiskei koidz extract prepared in Preparation Example 1, Baeksuo extract prepared in Preparation Example 2, ginkgo biloba extract prepared in Preparation Example 3, and the composite extract prepared in Preparation Example 4 .

Processed sample Treatment concentration (µg/ml) Platelet aggregation rate (%) Control 0 77.70 Angelica extract prepared in Preparation Example 1 80 50.33 160 34.33 Baeksuo extract prepared in Preparation Example 2 80 64.33 160 59.33 Ginkgo biloba extract prepared in Preparation Example 3 80 63.00 160 59.33 Composite extract prepared in Preparation Example 4 20 54.42 40 53.23 80 45.87 160 37.99 320 11.30

As shown in Table 2, when treating the composite extract prepared in Preparation Example 4, the platelet aggregation rate was very low overall compared to the case where the Angelica keiskei koidus extract, Baeksuo extract, and Ginkgo biloba extract were treated alone. These results are thought to be attributable to the synergistic action of platelet aggregation inhibition by the combination of Angelica keiskei koidus extract, Baeksuo extract and Ginkgo biloba extract.

4. Combination of complex extracts using thrombosis-induced animal models Antithrombosis Efficacy evaluation

Five week old male ICR-based mice (around 25-30 g) were purchased from Raon Bio. It was used for experiment after purifying and breeding for one week while supplying enough feed and water to the purchased mouse. As a breeding environment condition, 23±2℃ temperature, 55±15% relative humidity, 10 to 20 ventilations per hour, 12 hr lighting time (08:00 on, 20:00 off), and 150 to 300 Lux illumination conditions are used. Did. The thrombosis-induced animal model experiment was performed based on an experimental method such as Diminno. Specifically, 50 µl of a collagen and epinephrine mixed solution (1.4 ug/mouse+ 85 ug/mouse), which is a platelet aggregation inducer, was injected into the mouse tail vein. To investigate the antithrombotic effect of the drug sample, the drug sample was orally administered once in proportion to body weight 90 minutes before the injection of the platelet aggregation inducer. The experimental animals were 10 animals per group, and the drug samples were suspended in distilled water and administered. Subsequently, the antithrombotic efficacy of the drug was evaluated by calculating the percentage of the number of experimental animals protected from paralysis or death of the mouse hind limb caused by injection of a platelet aggregation inducer, that is, protection (%). After injection of the platelet aggregation inducer, the persistence of paralysis for 15 minutes or longer, recovery from death or paralysis was observed, and the antithrombotic effect of the drug sample was determined. The protection rate (Protection, %) of each experimental group was calculated using Equation 2 below.

[Equation 2]

C: Total population of the experimental group

D: dead or paralyzed population among the total population of the experimental group

Figure 2 shows the results of the anti-thrombotic efficacy evaluation of the complex extract using a thrombosis-induced animal model as a protection (%) value. In FIG. 2,'Control' of the X-axis is a group in which only vehicle (distilled water) as a drug sample is administered as a control group, and'ASA 100' is a positive control drug containing acetylsalicylic acid (Acetylsalicylic acid, or aspirin) as 100 mg/ It is a group administered in a dose of ㎏ (weight), and''ACG-1 extract' is a group in which the complex extract prepared in Preparation Example 4 is administered as a drug sample in a corresponding dose. In addition, Table 3 below shows the number and protection rates of the dead or paralyzed mice according to the experimental groups.

Drug administered in the experimental group Drug dosage excluding vehicle Number of dead or paralyzed mice Protection rate (%) Distilled water - 8/12 33.3 Acetylsalicylic acid 100 mg/kg (weight) 5/12 58.3 Composite extract prepared in Preparation Example 4 75 mg/kg (weight) 7/12 41.7 150 mg/kg (weight) 6/12 50.0 300 mg/kg (weight) 9/12 25.0

As shown in Table 3, the composite extract prepared in Preparation Example 4 showed an effect close to that of a commercial antithrombotic agent, acetylsalicylic acid (or aspirin).

5. Evaluation of cholesterol-lowering and neutral lipid-lowering efficacy of complex extracts using obesity-induced animal models

(1) Animal test method

Five week old male ICR-based mice (around 25-30 g) were purchased from Raon Bio. It was used for experiments after purifying and breeding for one week while supplying enough feed and water to the purchased mice. As a breeding environment, 23±2℃ temperature, 55±15% relative humidity, 10 to 20 ventilations per hour, 12 hr lighting time (08:00 lighting, 20:00 off), and 150 to 300 Lux lighting conditions are used. Did.

General dietary feed for laboratory animals (feed containing 6% fat) and high fat feed (feed containing 60% fat) were supplied from Raon Bio and used. There are 10 experimental animals per group, and the weight of the experimental animals during the breeding period was measured once a week. The normal diet group (n=10) was fed with a normal dietary feed, and distilled water was orally administered once a day for 12 weeks. In addition, the high-fat diet group (n=40) was divided into four groups of 10 animals, and the high-fat diet was fed to each experimental group and the drug sample was suspended in distilled water and orally administered once a day for 12 weeks. Table 4 below summarizes the experimental conditions for each experimental group.

Classification of experimental groups Processing contents Naive Oral administration of vehicle once a day with regular dietary feed Control Oral administration of vehicle once a day with high fat feed Control(+) A commercial ginkgo biloba extract product (manufacturer: GNC Holdings, Inc., US) is suspended in a vehicle with high fat feed, orally administered once a day at a dose of 173 mg/kg (weight). ACG-1 extract 75 The composite extract of Preparation Example 4 was suspended in a vehicle with high fat feed, orally administered once a day at a dose of 75 mg/kg (weight). ACG-1 extract 150 The composite extract of Preparation Example 4 was suspended in a vehicle with high fat feed, orally administered once a day at a dose of 150 mg/kg (weight).

* Vehicle: Distilled water

(2) Weight gain

During the entire experimental period, the weight of the experimental animals was measured at regular times every day, and the weight gain for 12 weeks was calculated based on this. Figure 3 shows the weight gain in the experimental results using the obese-inducing animal model. In addition, the weight gain of the obesity-induced animal model experiment results are shown in Table 5 below.

Classification of experimental groups Weight gain (g/12 weeks) Naive 8.5 Control 19.2 Control(+) 14.1 ACG-1 extract 75 19.0 ACG-1 extract 150 15.5

As shown in Table 5, the composite extract prepared in Preparation Example 4 exhibited an excellent anti-obesity effect.

(3) plasma neutral lipid and cholesterol

After completion of the experiment using an obese-derived animal model, triglyceride, total cholesterol and LDL cholesterol content in plasma of mice were measured using an automatic serum analyzer (Komelab 20XT, Thermo Electron, Louisville, CO, USA). FIG. 4 shows the triglyceride content in plasma among the experimental results using the obese-inducing animal model, FIG. 5 shows the total cholesterol content in plasma among the experimental results using the obese-inducing animal model, and FIG. 6 shows the obese-inducing animal Among the experimental results using the model, it shows the LDL cholesterol content in plasma. 4 to 6, the composite extract prepared in Preparation Example 4 showed excellent neutral lipid lowering effect, total cholesterol lowering effect and LDL cholesterol lowering effect.

Increased total cholesterol is known to be an important factor causing cardiovascular disease, such as hypertension. In addition, HDL cholesterol is known to be effective in improving and preventing arteriosclerosis by lowering cholesterol content in the blood by making cholesterol accumulated in peripheral tissues or blood into cholesterol esters and transporting it to the liver, but the LDL cholesterol content is It represents an inverse correlation. Therefore, the composition comprising the composite extract prepared in Preparation Example 4 of the present invention as an active ingredient can prevent, improve or treat obesity as well as prevent, improve and treat hyperlipidemia, arteriosclerosis, etc. through experiments. Could.

6. Preparation of pharmaceutical compositions

<6-1> Preparation of powder

2 g of the complex extract of Preparation Example 4

1 g of lactose

A powder was prepared by mixing the above components and filling the gas-tight fabric.

<6-2> Preparation of tablet

100 mg composite extract of Preparation Example 4

Corn starch 100 mg

Lactose 100mg

Stearic acid magnet 2mg

After mixing the above components, tablets were prepared by tableting according to a conventional tablet manufacturing method.

<6-3> Preparation of capsules

100 mg composite extract of Preparation Example 4

Corn starch 100 mg

Lactose 100mg

Magnesium stearate 2mg

After mixing the above components, the capsules were prepared by filling the gelatin capsules according to a conventional capsule preparation method.

<6-4> Preparation of ring

1 g composite extract of Preparation Example 4

1.5 g lactose

Glycerin 1 g

Xylitol 0.5 g

After mixing the above components, it was prepared to be 4 g per ring according to a conventional method.

<6-5> Preparation of granules

150 mg of the complex extract of Preparation Example 4

Soybean extract 50 mg

Glucose 200 mg

Starch 600 mg

After mixing the above components, 100 mg of 30% ethanol was added, dried at 60° C. to form granules, and then filled into the fabric.

<6-6> Preparation of Injection

100 mg composite extract of Preparation Example 4

Sodium metabisulfite 3.0 mg

Methylparaben 0.8 mg

Propylparaben 0.1 mg

Suitable amount of sterile distilled water for injection

After mixing the above ingredients, 2 ml of these were filled in an ampoule and sterilized to prepare an injection.

7. Preparation of food composition

<7-1> Preparation of flour food

0.5 to 5.0 parts by weight of the composite extract of Preparation Example 4 was added to 100 parts by weight of flour, and bread, cake, cookies, crackers and noodles were prepared using this mixture.

<7-2> Preparation of soup and gravy

0.1 to 5.0 parts by weight of the composite extract of Preparation Example 4 was added to soup and gravy to prepare a health-enhancing meat processing product, noodles soup and gravy.

<7-3> Preparation of ground beef

10 parts by weight of the composite extract of Preparation Example 4 was added to 100 parts by weight of ground beef to prepare a ground beef for health promotion.

<7-4> Manufacturing Dairy Products

5-10 parts by weight of the complex extract of Preparation Example 4 was added to 100 parts by weight of milk, and various dairy products such as butter and ice cream were prepared using the milk.

<7-5> Preparation of wire

The brown rice, barley, glutinous rice, and yulmu were alpha-polished by a known method to distribute the dried one, and then prepared with a powder having a particle size of 60 mesh with a grinder.

Black soybeans, black sesame seeds, and perilla seeds were also steamed and dried by a known method, and then distributed into a powder having a particle size of 60 mesh with a grinder.

It was prepared by mixing the above-prepared grains, seeds and complex extracts of Preparation Example 4 in the following proportions.

Grains (30 parts by weight of brown rice, 15 parts by weight of barley, 20 parts by weight of barley),

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds),

Composite extract of Preparation Example 13 (3 parts by weight),

Territory (0.5 parts by weight),

Ground sulfur (0.5 parts by weight)

<7-6> Preparation of health drinks

Liquid ingredients (0.5g), oligosaccharides (2g), sugar (2g), salt (0.5g), water (75g) and 5 g of the complex extract of Preparation Example 4 are homogeneously blended and then sterilized. It was manufactured by packaging in small packaging containers such as glass bottles and plastic bottles.

<7-7> Preparation of vegetable juice

Vegetable juice was prepared by adding 5 g of the complex extract of Preparation Example 4 to 1,000 ml of tomato or carrot juice.

<7-8> Preparation of fruit juice

Fruit juice was prepared by adding 1 g of the complex extract of Preparation Example 4 to 1,000 ml of apple or grape juice.

As described above, the present invention has been described through the above embodiments, but the present invention is not necessarily limited thereto, and various modifications can be made without departing from the scope and spirit of the present invention. Accordingly, the protection scope of the present invention should be construed to include all embodiments falling within the scope of the claims appended to the present invention.

Claims (4)

A pharmaceutical composition for preventing or treating dyslipidemia, comprising a complex extract consisting of a true Angelica extract, a white sallow extract and a ginkgo leaf extract as an active ingredient.
The pharmaceutical composition for preventing or treating dyslipidemia according to claim 1, wherein the dyslipidemia is at least one selected from the group consisting of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia.
A food composition for preventing or improving dyslipidemia, comprising a complex extract consisting of a true Angelica extract, a white sorghum extract and a ginkgo leaf extract as an active ingredient.
The food composition for preventing or improving dyslipidemia according to claim 3, wherein the dyslipidemia is at least one selected from the group consisting of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia.

Images